Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The fight against osteoarthritis (OA) is on at the Kennedy Institute’s Centre for Osteoarthritis Pathogenesis. We have been awarded two research grants looking at different aspects of OA with the ultimate aim of developing novel treatments for this painful and disabling condition.

OA is the most common type of arthritis in the UK, causing the joints to progressively become painful and stiff and making everyday tasks very difficult for patients. When a joint develops osteoarthritis, the cartilage on the end of the bone gradually roughens and becomes thin, whilst the bone underneath thickens.

Osteoarthritis is also the biggest healthcare challenge in rheumatology as there are no effective treatments available; patients rely on painkillers and eventually joint replacement surgery.  

Professor Tonia Vincent, lead researcher for both projects says of the awards: “These two projects are deeply embedded within our OAPathogenesis Centre and will help to stratify patients for future clinical trials and to identify novel therapeutic targets’”

Cartilage repair.

In collaboration with researchers at Utrecht University, this innovative study will look to validate novel markers of cartilage repair in OA patients, paving the way for a potential powerful, cheap, and acceptable treatment for many with advanced OA.

New evidence suggests that osteoarthritic cartilage is able to repair itself if the adverse mechanical environment of the joint is corrected; this has a significant and sustained improvement in pain, but also on cartilage ‘re-growth’. Researchers have identified molecules – biomarkers – that are activated following joint injury and likely drive repair responses, in mouse models. Identifying these biomarkers of successful repair in OA patients has the potential to change the way we view disease, empower patients into believing that their disease is modifiable and open up new possibilities for cheaper, globally applicable treatments.

Project title: Identifying markers in the synovial fluid of patients with osteoarthritis (OA) that predict their ability to repair cartilage
Funder: Arthritis Research UK Project Grant

 

Novel non-invasive imaging method.

The team at the Kennedy Institute, led by Professor Tonia Vincent and Dr Ngee Han Lim, will work to develop a novel imaging agent that can be combined with microCT scanning to create a sensitive, quantitative cartilage assessment tool in OA.

Investigating the pathways that cause OA has been very challenging as the human condition is very variable in its course, it is difficult to obtain tissues from patients and we currently have no way of detecting early disease. In this context, animal models of OA have significant utility because disease can be studied at all stages of the condition, tissues are readily available, and the onset of disease is known.

Evaluation of joint damage both in clinic and in animal models of OA is hampered by the inability to image cartilage accurately and non-invasively. A non-invasive imaging method that would be able to visualise the degradation of cartilage over time would greatly reduce the numbers of animals being used in arthritis research, as well as being potentially translatable into a clinical imaging agent for early OA in humans.

Project title: Development of novel imaging agents for the prospective quantification of joint damage to reduce animal numbers is osteoarthritis research
Funder: NC3Rs – National Centre for the Replacement, Refinement & Reduction of Animals in Research

Similar stories

NDORMS researchers awarded for Dupuytren research

Awards Hand Kennedy Main

Three NDORMS researchers have received awards from the International Dupuytren Society, a patient organisation that brings together Dupuytren Disease patient societies from across the world.

Hope for rheumatoid arthritis patients who are non-responsive to anti-TNF

Arthritis Kennedy Main

New research published in The Lancet shows that tocilizumab is a more effective treatment than rituximab for rheumatoid arthritis patients with a poor response to anti-tumour necrosis factor (TNF).

A new study maps the expression of innate immune receptors during the course of arthritis

Arthritis Kennedy Main

The research, which was a collaboration with researchers from Oxford University and Queen Mary University of London and published in Journal of Autoimmunity, looked at changes in receptors known as toll-like receptors (TLRs) in arthritis at different stages of disease.

International Women's Day

Department Main

It’s International Women's Day! This year’s theme is #Choosetochallenge. We’re celebrating some of the amazing women at NDORMS, and asking them what changes they’d like to see in medical sciences over the next 100 years.

Patients and carers invited to join new group helping to shape research and treatment of bones, muscles and joints

Main PPI

Oxford’s newest patient partner group, OPEN ARMS launches today to explore the causes, treatment and care for patients with musculoskeletal conditions. Its first three patient partners explain why they are involved and invite other members of the public to join the team.

NDORMS academics named NIHR Senior Investigators

Main

Congratulations to Professor Jonathan Rees who has been announced as a National Institute of Health Research (NIHR Senior Investigator).